Reported Earlier, Innovent Dosed First Participant In Phase 3 Clinical Study Of IBI310 In Combination With Sintilimab For MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Author: Benzinga Newsdesk | March 27, 2024 02:17am
Neoshot is the first Phase 3 clinical trial (NCT05890742) in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. The study will evaluate the safety and efficacy of IBI310 combined with sintilimab for neoadjuvant therapy, compared with adjuvant chemotherapy after radical surgery for MSI-H/dMMR colon cancer. The primary endpoints are pathologic complete response (pCR) rate and event-free survival (EFS).
Posted In: IVBIY